PZParounak Zelveian

Parounak Zelveian

*This is an algorithmically generated author record based on publicly available information.

Parounak Zelveian has a total of 139 co-authors. Here are the top co-authors by number of shared publications:

  • Heghine Gharibyan

    Armenian Union for the Prevention and Study of Hypertension , 27/40 M. Saryan str., Yerevan 0002

    9 shared publications
  • Siranush Aroyan

    Armenian Union for the Prevention and Study of Hypertension , 27/40 M. Saryan str., Yerevan 0002

    6 shared publications
  • Zoya Hakobyan

    Armenian Union for the Prevention and Study of Hypertension , 27/40 M. Saryan str., Yerevan 0002

    6 shared publications
  • Arevik Melkonyan

    Armenian Union for the Prevention and Study of Hypertension , 27/40 M. Saryan str., Yerevan 0002

    5 shared publications
  • Avag Avagyan

    Armenian Union for the Prevention and Study of Hypertension , 27/40 M. Saryan str., Yerevan 0002

    5 shared publications
  • Jirar Topouchian

    Diagnosis and Therapeutic Center, Hôtel Dieu Hospital, Paris, France

    5 shared publications

Latest Publications

  • Open Access

    The LEASH Trial: Rationale and Study Design for Early Rosuvastatin-Ezetimibe Combination Compared with Stepwise Rosuvastatin in High/Very-High Cardiovascular Risk.

    by Borut Jug, Parounak Zelveian, Ivan Pećin, Martin Bergmann, Dragan Simić, Laszlo Mark, Maciej Banach

    Introduction: Contemporary guidelines recommend early achievement of stringent LDL-C goals in patients at high cardiovascular risk. The LEASH trial evaluates upfront rosuvastatin/ezetimibe combination therapy with a stepwise intensification strategy in treatment-naïve patients. Material and methods: LEASH is an international, prospective, multicentre, randomized, open-label trial. Treatment-naïve adults aged <70 years are randomized 1:1 within country and risk strata. Arm 1 starts with rosuvastatin 20 mg/day with protocol-directed stepwise escalation; Arm 2 starts with rosuvastatin/ezetimibe 20/10 mg/day (SPC) with subsequent intensification. Treatment is reassessed at 4, 8, and 12 weeks. The primary endpoint is proportion of patients achieving complete LDL-C goal at week 12, defined as ≥50% reduction from baseline plus LDL-C<1.8 mmol/L (<70 mg/dl) for high-risk or <1.4 mmol/L (<55 mg/dl) for very-high-risk patients. Secondary endpoints include early goal attainment at week 4 and 8, lipoproteins changes, adherence, between-arm differences, and safety. Results: The LEASH trial is the first RCT to evaluate the early (4–12 weeks) efficacy and safety of an upfront SPC (rosuvastatin/ezetimibe) for LDL‑C reduction and goal attainment in high and very‑high cardiovascular risk patients. The results will inform not just whether combination therapy is effective in this population, but - critically - whether earlier initiation shortens the time to LDL‑C goal attainment and, consequently, reduces the risk of first and subsequent cardiovascular events. Conclusions: LEASH will assess whether upfront statin/ezetimibe combination therapy differs from conventional stepwise statin‑based lipid‑lowering intensification in early LDL‑C reduction and goal achievement. Therapy adherence and safety differences between the approaches will also be assessed.

  • Open Access

    May Measurement Month 2023: results of an opportunistic blood pressure screening campaign in Armenia

    by Parounak Zelveian, Avag Avagyan, Zoya Hakobyan, Heghine Gharibyan, Arevik Melkonyan, Siranush Aroyan, Lusine Hazarapetyan, Svetlana Grigoryan, Hamlet Hayrapetyan, Thomas Beaney, et al.

    Elevated blood pressure (BP) is a growing burden and is the leading cause of mortality and disability-adjusted life years globally. May Measurement Month (MMM) is a global initiative aimed to raise awareness of high BP and to act as a temporary solution to the lack of screening programs worldwide and was conducted in Armenia in 2023. Participants aged 18 years and older were recruited using convenience sampling across Armenia, primarily at hospitals, clinics, and pharmacies, as well as in workplaces, homes, and public areas. Three seated BP readings were taken for each participant, and a structured questionnaire was administered to collect information on demographics, lifestyle factors, and comorbidities. Hypertension was defined as a systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg or being on BP-lowering medication. Controlled BP was defined as being on BP-lowering medication with a BP <140/90 mmHg. A total of 5,965 individuals were screened, with a mean (standard deviation) age of 49.3 (16.6) years, and 53.9% of the cohort being female. The majority (98.6%) were screened in a hospital, clinic, or pharmacy setting. The remaining participants were screened in public areas (indoor/outdoor) (0.3%), at the workplace (0.3%), or at home (0.4%). The overall prevalence of hypertension was found to be 41.5% (n=2,476). Of these hypertensive participants: 49.0% (n=1,213) were aware of their condition and 43.4% (n=1,075) were receiving antihypertensive medication. Among those on BP-lowering medication, 40.7% (n=437) had controlled BP. Consequently, only 17.6% of all participants with hypertension achieved BP control. The MMM campaign in Armenia identified a substantial number of participants with untreated or inadequately controlled hypertension. The current situation, characterised by an insufficient hypertension control rate, necessitates continuous and rigorous change.


  • Open Access

    Accuracy of the Withings BPM Pro 2 (WPM07) Device for Self-Blood Pressure Measurements in the General Populations According to the International Organization for Standardization Universal Standard (ISO 81060-2:2018/AMD 2:2024) Protocol

    by Parounak Zelveian, Zoya Hakobyan, Jirar Topouchian, Avag Avagyan, Heghine Gharibyan, Roland Asmar

    Background: The accuracy of blood pressure (BP) measurements performed by electronic devices is crucial in clinical practice. International professional societies emphasize the need for rigorous, standardized validation of electronic BP measuring devices to ensure their accuracy and reliability. Objective: This study evaluated the accuracy of the Withings BPM Pro2 (WPM07) upper‑arm oscillometric BP monitor in the adult general population using the ISO 81060‑2:2018/AMD 2:2024 Universal Standard. Methods: Following the ISO same‑arm sequential measurement protocol, 89 eligible pre-selected participants underwent paired test‑device and mercury reference auscultatory measurements. Nine BP measurements were performed on each participant, four with the tested device and five with the auscultatory method. The accuracy of BP measurements was assessed based on the difference between simultaneous measurements taken by two observers and those displayed by the tested device using ISO Criterion 1 (mean and standard deviation of test–reference differences) and Criterion 2 (within‑subject variability of averaged difference values). Results: Eighty-nine participants underwent the BP measurements protocol, data from 87 were analyzed after excluding 2 participants due to excessive BP variability. Inter‑observer agreement for reference measurements was 0.64 ± 2.14 mmHg for systolic BP (SBP) and 0.39 ± 1.98 mmHg for diastolic BP (DBP). ISO criterion 1 was met with mean test–reference differences of 1.0 ± 4.9 mmHg (SBP) and 0.6 ± 4.1 mmHg (DBP) below ISO requirements (≤ 5± 8 mmHg). ISO criterion 2 was also satisfied, with within‑subject standard deviations of 3.50 mmHg (SBP) and 3.01 mmHg (DBP), well below the ISO thresholds (≤ 6.87/6.91 mmHg). Conclusion: The BPM Pro2 (WPM07) fulfills the ISO 81060‑2:2018/AMD 2:2024 accuracy requirements and is suitable for reliable home BP self‑measurement in adults.


  • Hypertension Control in Men and Women: The Role of Perindopril-based Single-pill Combination Treatment

    by Jana Brguljan-Hitij, Zbigniew Gaciong, Dragan Simić, Peter Vajer, Parounak Zelveian, Irina E. Chazova, Bojan Jelaković

  • Open Access

    May Measurement Month 2022: an analysis of blood pressure screening results from Armenia

    by Parounak Zelveian, Zoya Hakobyan, Heghine Gharibyan, Siranush Aroyan, Arevik Melkonyan, Lusine Hazarapetyan, Svetlana Grigoryan, Thomas Beaney, Gabriele Kerr, Neil R Poulter

    The May Measurement Month (MMM) campaign was carried out in Armenia in 2022 with the aim of raising awareness of raised blood pressure (BP). Here, we report on the findings of the campaign. Adults aged ≥18 years were recruited opportunistically in public areas, both indoor and outdoor, as well as in primary and secondary healthcare centres. Three seated BP readings were taken for each participant, along with completion of a questionnaire on demographics, lifestyle factors, and comorbidities. Hypertension was defined as a systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg or being on antihypertensive medication. Controlled BP was defined as being on antihypertensive medication with a BP <140/90 mmHg. Multiple imputation was used to estimate any missing BP readings. In total, 11 618 participants were screened, with a mean age of 52.4 (SD 16.5) years and 55.7% of whom were female. Of all participants, 5,999 (51.6%) had hypertension, of whom 3,729 (62.2%) were aware, and 3,203 (53.4%) were on antihypertensive medication. Of those on antihypertensive medication, 1,130 (35.3%) had controlled BP, and of all participants with hypertension, only 18.8% had controlled BP. In total, 4,869 (41.9%) were found to have either untreated or inadequately treated hypertension. The MMM campaign in Armenia identified significant numbers of participants with either untreated or inadequately treated hypertensives. We found that the percentage of hypertensives who are not adequately treated is still substantial in Armenia, which is a vital contributor to the growing burden of non-communicable diseases. May Measurement Month is a pragmatic and reasonably inexpensive tool to improve public awareness of BP in the general population.


  • Open Access

    Management of patients with hypertension and chronic kidney disease referred to Hypertension Excellence Centres among 27 countries. On behalf of the European Society of Hypertension Working Group on Hypertension and the Kidney

    by Jean-Michel Halimi, Pantelis Sarafidis, Michel Azizi, Grzegorz Bilo, Thilo Burkard, Michael Bursztyn, Miguel Camafort, Neil Chapman, Santina Cottone, Tine de Backer, et al.

    Objective Real-life management of patients with hypertension and chronic kidney disease (CKD) among European Society of Hypertension Excellence Centres (ESH-ECs) is unclear : we aimed to investigate it. Methods A survey was conducted in 2023. The questionnaire contained 64 questions asking ESH-ECs representatives to estimate how patients with CKD are managed. Results Overall, 88 ESH-ECS representatives from 27 countries participated. According to the responders, renin-angiotensin system (RAS) blockers, calcium-channel blockers and thiazides were often added when these medications were lacking in CKD patients, but physicians were more prone to initiate RAS blockers (90% [interquartile range: 70-95%]) than MRA (20% [10-30%]), SGLT2i (30% [20-50%]) or (GLP1-RA (10% [5-15%]). Despite treatment optimisation, 30% of responders indicated that hypertension remained uncontrolled (30% (15-40%) vs 18% [10%-25%]) in CKD and CKD patients, respectively). Hyperkalemia was the most frequent barrier to initiate RAS blockers, and dosage reduction was considered in 45% of responders when kalaemia was 5.5-5.9 mmol/L. Conclusions RAS blockers are initiated in most ESH-ECS in CKD patients, but MRA and SGLT2i initiations are less frequent. Hyperkalemia was the main barrier for initiation or adequate dosing of RAS blockade, and RAS blockers' dosage reduction was the usual management.


  • Open Access

    May Measurement Month 2021: an analysis of blood pressure screening results from Armenia

    by Parounak Zelveian, Zoya Hakobyan, Heghine Gharibyan, Arevik Melkonyan, Samvel Hayrumyan, Siranush Aroyan, Lusine Hazarapetyan, Svetlana Grigoryan, Thomas Beaney, Gabriele Kerr, et al.

    Elevated blood pressure (BP) is a growing burden worldwide and is the leading cause of mortality and disability-adjusted life years all over the world. May Measurement Month (MMM) is a global initiative aimed to increase awareness of high BP initiated by the International Society of Hypertension, to identify individuals in need of improved hypertension care, and to improve BP screening worldwide. An opportunistic cross-sectional survey of volunteers aged ≥18 years was carried out in accordance with standard MMM protocol in 2021. The study was conducted in public areas, both indoor and outdoor, as well as in primary and secondary healthcare centres. A total of 5777 individuals (mean age 51.8 ± 16.1 years, 49.8% female) were screened. After imputation, 45.7% participants had hypertension and 43.7% of them were aware of their high BP. Of 2640 participants with hypertension, 887 (33.6%) were on antihypertensive treatment, of whom 32.4% were on single medication, 29.7% on two medications, and 37.9% on three or more. Only 42.2% of those on medication had controlled BP (<140/90 mmHg), whereas of the participants with hypertension overall, 14.2% had controlled BP. We found that the prevalence of inadequately treated hypertension remains high in Armenia and may represent a vital contributor to the growing burden of non-communicable diseases.


  • Open Access

    Validation of the Withings BPM Core Device for Self-Blood Pressure Measurements in General Population According to the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization Universal Standard

    by Zoya Hakobyan, Parounak Zelveian, Jirar Topouchian, Lusine Hazarapetyan, Roland Asmar

    Background: Most of the scientific societies recommend assessing the accuracy of electronic devices for blood pressure (BP) measurements using established validation protocol. Objective: To determine the accuracy of the BP measurements using the Withings BPM Core device in the general population according to the "Universal Standard (ISO 81060-2:2018/AMD 1:2020)". Methods: The Withings BPM Core is an oscillometric device measuring BP at the brachial level. The study was performed according to the "Universal Standard (ISO 81060-2:2018/AMD 1:2020) protocol" using the same-arm sequential BP measurement method. Subjects (n & GE; 85) fulfilling the age, gender, BP, and cuff distribution criteria of the protocol were included. Analysis was performed as required by the Universal protocol using Criterion 1 - differences between observers' mercury sphygmomanometer reference measurements and test device BP values (test versus reference) and their standard deviation (SD); and Criterion 2 - The SD of the mean BP differences between the test device and reference BP per subject. Results: Eighty-six subjects were selected, 85 of whom were included. The mean BP differences between the simultaneous two observers' measurements were -0.2 & PLUSMN; 2.1 mmHg for systolic BP (SBP) and 0.3 & PLUSMN; 2.1 mmHg for diastolic BP (DBP). For validation criterion 1, the mean difference & PLUSMN; SD between the reference and device BP values was -0.6 & PLUSMN; 4.8 mmHg for SBP and 0.1 & PLUSMN; 3.7 mmHg for DBP (<5 & PLUSMN; 8 mmHg for both SBP and DBP). For criterion 2, the SD of the mean BP differences between the test device and reference BP per subject was 3.2/2.6 mmHg for SBP and DBP (<6.91/6.95 mmHg). Conclusion: The results of this study showed that the Withings BPM Core oscillometric device for home BP measurement fulfilled the accuracy requirements of the (ISO 81060-2:2018/AMD 1:2020) Universal protocol in the general population.


  • Open Access

    Features of Atrial Fibrillation Pathogenesis and Prognosis in Chronic Obstructive Pulmonary Patients during the COVID-19 Pandemic

    by Lusine G. Hazarapetyan, Parounak H. Zelveian, Svetlana V. Grigoryan

    Background: Atrial fibrillation (AF) is observed in arterial hypertension, heart failure, ischemic heart disease, and pulmonary pathology, particularly, chronic obstructive pulmonary disease (COPD). COPD in turn is a risk factor for developing these cardiovascular diseases and various arrhythmias. In the coronavirus disease (COVID) situation, such comorbid patients are the most vulnerable group with a high risk of adverse outcomes. The relevance of the relationship between COPD and coronavirus infection is explained by the similarity of clinical and pathophysiological manifestations, creating more difficulties in diagnosing and determining rational treatment. The aim of the current study is to explore the role COPD plays in the onset and progression of AF, especially in the situation of COVID-19. Methods: We searched PubMed databases and included studies with information on comorbid patients suffering from COPD and AF, as well as similar patients in the context of COVID-19. Results: A modern view on the problem of comorbidity of COPD and AF is presented. In the presence of cardiorespiratory comorbidity, symptoms of mutual worsening of the clinical course are observed, due to the commonality of some links of pathogenesis, including hypoxia, hemodynamic disturbances, activation of the sympathoadrenal system, systemic inflammation, and development of fibrosis, leading to myocardial remodeling, a decrease in the effectiveness of the therapy, and a worsening prognosis, especially in the context of COVID-19. Conclusions: The results of a study of the features of the pathogenesis and course of AF in COPD are presented, as well as the formation and progression of this comorbid pathology in the context of the COVID-19 pandemic.


  • Open Access

    Accuracy of the Withings BPM Connect Device for Self-Blood Pressure Measurements in General Population – Validation According to the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization Universal Standard

    by Jirar Topouchian, Parounak Zelveian, Zoya Hakobyan, Heghine Gharibyan, Roland Asmar

    Background: As recommended by various authorities and scientific societies, electronic devices for blood pressure (BP) measurements must undergo independent clinical validations for accuracy assessment. Objective: To assess the accuracy of the Withings BPM Connect device in the general population according to the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization “AAMI/ESH/ISO Universal Standard (ISO 81060– 2:2018)”. Methods: The Withings BPM Connect device measures BP at the brachial level using the oscillometric method. According to this protocol using the same-arm sequential BP measurement method, subjects (n ≥ 85) fulfilling the age, gender, BP and cuff distribution criteria must be included. Two criteria are used for the analysis: Criterion 1: differences between observers’ mercury sphygmomanometer reference measurements and test device BP values (test versus reference) and their standard deviation (SD) must be ≤ 5 ± 8 mmHg for both systolic (SBP) and diastolic BP (DBP). Criterion 2: the SD of the mean BP differences between the test device and reference BP per subject must be ≤ 6.91/6.62 mmHg for SBP/DBP. Results: Ninety-two subjects were selected, 85 of whom were included. For validation criterion 1, the mean difference ± SD between the reference and device BP values was 0.6 ± 5.3 mmHg for SBP and 2.1 ± 4.3 mmHg for DBP. For criterion 2, the SD of the mean BP differences between the test device and reference BP per subject was 4.2/3.6 mmHg (SBP/DBP). These results fulfilled the AAMI/ESH/ISO Universal Standard (ISO 81060– 2:2018) protocol requirements. Conclusion: The Withings BPM Connect oscillometric device for home BP measurement fulfilled all of the accuracy requirements of the AAMI/ESH/ISO Universal Standard (ISO 81060– 2:2018) in general population and consequently can be recommended for home BP measurements.